Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 2/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.45 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
| ▸ | GAPDH | P04406 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | STAT6 | P42226 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998090 | 0.90 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL30216733 | 0.86 | EHMT1 (0.45) | EHMT1ADORA3ADORA2ASLC28A1GMPS | |
| SCHEMBL160357 | 0.86 | ADORA3 (0.53) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL9495963 | 0.85 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL28160452 | 0.84 | ADORA3 (0.45) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL6935380 | 0.83 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL9231750 | 0.82 | ADORA3 (0.49) | EHMT1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5742060 | 0.82 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL3317153 | 0.82 | ADORA2A (0.48) | EHMT1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1920532 | 0.81 | ADORA3 (0.48) | EHMT1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348315-B2 | Methods of treating heart failure with modified ATP, ADP and AMP compounds | THE UNIVERSITY OF CONNECTICUT (US) | 2008-03-25 | — | — | US | disclosed |
| US-20030186929-A1 | Methods of treating heart failure with modified ATP, ADP and AMP compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-10-02 | — | — | US | disclosed |
| US-6255292-B1 | INCREASING CELLULAR CONTRACTIONS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2001-07-03 | — | — | US | disclosed |
| US-5712258-A | Inotropic ADP and ATP analogues and their pharmaceutical compositions | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-01-27 | — | — | US | disclosed |
| WO-1996029345-A1 | NOVEL INOTROPIC AGENTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186929-A1 | Methods of treating heart failure with modified ATP, ADP and AMP compounds | ATP5MF, ATP5MG, ATP2A1 | EHMT1 1868/4885PI4KA 2498/4885PI4K2B 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.